In late 2025, the FDA approved an oral semaglutide formulation (Wegovy oral) for weight management at 25mg and 50mg doses, with clinical trials showing 13-14% body weight reduction
"The DSA obliges platforms to address risks of illegal content and goods being disseminated on their sites," and the Commission is monitoring compliance and won't hesitate to open further proceedings, according to the spokesperson
Self-switching or overlapping treatments can lead to risks and are not recommended
The ease of qualifying for GLP-1 drugs reduced annual bariatric surgeries by 25% in 2023.[13] The 2024 numbers are likely to be equally impactful
According to customer reviews, Ros services are helpful for people who wish to consult a doctor online
With our expertise in talent management and brand strategy, well connect you with the right endorsers who can drive real results